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1 Introduction
From 2017 to 2018 the number of scientific publications found via PubMed search using the key-
word “Machine Learning” increased by 46% (4,317 to 6,307). The results of studies involving
machine learning, artificial intelligence (AI), and big data have captured the attention of health-
care practitioners, healthcare managers, and the public at a time when Western medicine grapples
with unmitigated cost increases and public demands for accountability. The complexity involved
in healthcare applications of machine learning and the size of the associated data sets has afforded
many researchers an uncontested opportunity to satisfy these demands with relatively little over-
sight. While there is great potential for machine learning algorithms to positively impact healthcare
related costs and outcomes, its deployment cannot be regarded in the same way a shipping opti-
mization algorithm is considered at an Amazon warehouse. Those involved in the care of the infirm
appreciate the incredibly high expectation for performance and more importantly the unique obliga-
tion to primum non nocere (first do no harm).
In a recent Nature Medicine article, “The Artificial Intelligence Clinician learns optimal treatment
strategies for sepsis in intensive care,” [1] Komorowski and his coauthors propose methods to train
an artificial intelligence clinician to treat sepsis patients with vasopressors and IV fluids. In this post,
we will closely examine the claims laid out in this paper. In particular, we will study the individual
treatment profiles suggested by their AI Clinician to gain insight into how their AI Clinician intends
to treat patients on an individual level. While the work has the potential to contribute to the ad-
vancement of the field, its unqualified claims which have been repeated throughout the lay press [2]
promote an unrealistic capability. These claims jeopardize future prospective applications of health-
care associated machine learning algorithms and could cause great harm to patients if prospectively
deployed.
2 Terminology
Discussion of Reinforcement Learning as applied by Komorowski et al. to the treatment of sepsis
requires understanding of several key terms. Definitions of these terms are provided so that the
reader can better follow our work. Readers familiar with this topic can skip this section and begin
their reading at Summary.
State: The summary of all of a patient’s clinical measurements (e.g., heart rate, leukocyte count,
gender etc.) at a given point in time. In this work every 4-hour period of patient data is assigned to
one of 750 unique states.
Action: A combination of two intervention categories (IV fluid and vasopressor treatment). IV fluid
and vasopressor treatments are each divided into 5 treatment levels for a total of 25 permutations
∗These authors contributed equally to this work.
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(5x5). Though there are many types of IV fluids and vasopressors, for simplicity, the authors nor-
malize them to construct the two intervention categories (vasopressors and IV fluids).
Policy: This is the recommended action to take for a given state. In this context, for a given patient
state, the policy is the recommended amount of vasopressors or IV fluids to give.
Value: The value of a policy is defined in terms of the likelihood of survival under the proposed
policy. In a retrospective setting, this requires “Counterfactual Reasoning”, i.e. what-if the patients
were dosed according to the AI clinician’s policy rather than the existing policy (that is, the policy
that generated the observed data)?
Sepsis: A dysregulated immune response to infection that results in tissue and end organ damage.
Hypotension: The metabolic processes of the body require that oxygenated blood be delivered to
the organs of body with sufficient pressure. Mean arterial pressures of < 65 mm Hg are considered
pathologic.
Septic Shock: A condition that is diagnosed when a septic patient experiences a persistently low
blood pressure that is not improved by treatment with IV fluids, requires vasopressor support, and
is suspected of causing elevated lactate levels greater than 2mmol/L. Vasopressors and IV fluids are
the most prevalent adjuncts used to re-establish physiological MAP levels ≥ 65.
Figure 1: There exists a small population of hypotensive patients with sepsis that requiring vaso-
pressors, but have normal lactic acid levels. By virtue of their normal lactate they are not labeled as
having septic shock.
3 Summary
The authors approach treating septic patients using a Reinforcement Learning (RL) framework [3].
This means that there is an environment (a sick patient) and an agent (a clinician) who acts to
maximize some reward (patient health). Generally speaking, this is an appropriate way to automate
or create “clinician-in-the-loop” algorithms for the treatment of a patient’s experiencing an evolving
clinical phenotype (state). While there are many different RL methods that can be used to approach
patient treatment, Komorowski et al. chose to use a “Policy Iteration” method (a great introduction
to this method can be found in [4]). Given sufficient information about the underlying system, this
method evaluates a large state space and converges to an optimal policy: a policy that maximizes the
expected value, which in this setting corresponds to minimizing patient mortality.
To utilize this method, the authors use real patient data from the public Medical Information Mart
for Intensive Care III (MIMIC III) [5] dataset to construct their environment and provide a clinical
baseline treatment policy for comparison/evaluation. Their RL “environment” consists of patient
features (including comorbidities) clustered into 750 states and their RL “actions” consist of two
intervention categories (vasopressors administration and IV fluids administration) binned into 25
actions (see the Terminology section for more explanation). After the patient trajectories are com-
pressed into these discrete states, the authors construct a 750 x 750 x 25 3-D transition matrix (or 25
different 750 x 750 transition matrices) from the observations in their dataset. Put simply, suppose
your patient is in state 517, and historically, clinicians treat patients in this state with action 8. Given
the current patient state 517 and clinician action 8, there is an underlying probability that the patient
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will transition to each of the 750 states in the environment. Unfortunately, the authors have provided
no evidence of goodness of fit [6] for this transition matrix to the patient state data (this will be the
topic of a future post).
If one accepts this representation of patient states, then using the probabilities in this transition
matrix, you can predict a septic patient’s entire clinical course given the treatment regimens. That
is, the model provides an in silico representation of the entire septic ICU population. The authors
use this empirically-derived transition matrix to implement the policy iteration method; this enables
them to construct an AI Clinician that learns how to dose patients with vasopressors and IV fluids.
Figure 2: Estimated policy value for the observed clinician policy, the learned AI policy, the zero
drug policy, and a random policy for 500 realizations of the environment. Figure taken from [1].
Figure 2 shows the estimated policy value for four different agents after 500 iterations whereby
the environment (including states and transition probabilities) are constructed, and a new dosing
policy is explored using Policy Iteration [4]. The value of the dosing policies are determined using
survival or expiration as the terminal state (see equation (5) in [1]). The chosen policy, e.g. best,
is the one with the highest expected policy value. The results seem promising: the best AI policy
yields a much higher expected value than all of the clinician policies. However, a serious concern
arises too: for most of the realizations, the zero drug policy outperforms the clinician policy. This is
counterintuitive and does not pass the smell test.
How is it more valuable on average to NOT intervene on a population of septic patients?
Perhaps there is an underlying problem in the proposed model or in the evaluation metric that consis-
tently allows this zero-drug policy to outperform the clinician policy. To understand their methods
in more detail, we reached out to the authors on October 31st, 2018 to obtain the code and data
used in their study to train the AI Clinician (which, per their publication, is available by request to
the corresponding authors). They responded that the code would be made available through their
website, but several months later is still unavailable. Hence, we decided to reproduce their work
using the MIMIC III dataset and a careful review of their methods.
4 Results from Implementing Their Methods
A note on reproducibility: Reproducibility is one of the cornerstones of scientific progress. It is
imperative that scientists be able to reproduce someone else’s findings; this allows future researchers
to build on previous work as well as verify that controversial findings are valid. In computational
disciplines such as biomedical informatics, making codes available via platforms such as GitHub is
an important step towards reproducibility.
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To investigate why non-intervention outperformed clinician policy, we attempted to reproduce the
results of Komorowski et al. We utilized data from 5,366 septic patients from the MIMIC III dataset
in which every patient received both vasopressors and fluids. We chose this cohort to ensure that
the patients evaluated by the AI Clinician required clinical intervention. Data was binned into one-
hour intervals, whereas data in Komorowski et al.s paper were binned into four-hour intervals. We
use one-hour intervals to better approximate the dose-to-response time for fluid resuscitation and
vasopressor intervention. We normalized and discretized clinician actions into the same 25 actions
and similarly followed the methods described in the paper. Below is a summary of clinician actions
across the cohort:
Figure 3: Summary of the real clinician actions in our MIMIC III cohort.
In terms of expected value, the 95-percentile of AI Clinician policy performs much better than the
actual clinicians, but what does this AI Clinician’s policy look like? Below we show the AI Clinician
(labeled “RL Agent”) and an actual clinician’s dosing suggestions for a given patient throughout
their clinical course plotted alongside the patient’s Mean Arterial Pressure (MAP).
Despite having high expected return values, the AI Clinician fails to learn the relationship between
MAP and the need for vasopressors and IV fluids (see hours 20 through 35). Notice that for a
significant portion of time the patient’s MAP is below the recommended target of 65 mm Hg [7],
and the AI Clinician does not recommend any treatment. So, why does the AI Clinician yield such
high expected return, yet misses several hours of critical hypotensive episodes? In our recreation
of their work, we believe to have found the answer: Both the representation of the system (patient
state-space and clinician actions) and how the policies are evaluated (the particular method of
counterfactual reasoning) skew the expected returns of the AI Clinician.
5 Policy Evaluation
5.1 Importance Sampling Introduces Bias in Evaluating the AI policy in Patients with Poor
Outcomes
Komorowski et al. measure the expected value of the AI Clinicians policy using importance sam-
pling. In very simple terms this means that certain input parameters in a simulation have more
significance than others . In the context of the AI Clinician’s training, actions that closely matched
a clinician’s and resulted in good outcomes were given the highest weight in training. This seems
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Figure 4: Comparison of the expected policy value for the clinician policy and AI policy for 500
realizations of the environment. The lower expected policy values arise because our cohort is inher-
ently more sick (our cohort has a mortality rate of 40%). Given the reward for 90-day survival is
+100 and the reward for death is -100, 40% mortality in the population roughly corresponds to an
expected policy value of 15 - 20. The best AI policy gives an expected policy value of 40, which
roughly corresponds to a 30% mortality ((70% x 100 ) - (30% x -100)).
like a reasonable approach; however, it has the effect of discounting patterns learned from medi-
cally complex patients who deteriorated despite the clinical teams best attempt to save the patient
(remember 90-day survival is a very challenging goal to meet for some very sick ICU patients). This
approach also has the perverse effect of disproportionately rewarding simple decisions, like taking
no action on a stable patient.
The AI Clinician is built from retrospective data and was never able to directly interact with a real
patient environment to determine its effectiveness. Traditionally, Reinforcement Learning works
by allowing the agent (in our case, the AI Clinician) to act on the environment and learn optimal
strategies via trial-and-error, an approach that would be patently unethical if applied prospectively
to real patients. To train the AI Agent Komorowski et al. created a “simulated ICU” (i.e. the
in silico environment, see Summary). The AI Clinician is then graded on its performance in this
oversimplified in silico ICU environment.
Importance sampling, as used by Komorowski et al., represents a middle ground between the above
concepts, the grading the AI Clinician performance in their created in silico ICU and its prospective
performance in a real ICU. Trajectories are navigated using the real clinicians policy, and the most
weight is given to the cases in which the AI Clinicians decisions most closely approximated the real
clinicians decisions. In the final policy evaluation, almost no value (positive or negative) is given to
trajectories for which the AI Clinician tries something significantly different than the real clinician,
regardless of if it would have harmed or improved a patient’s outcome. Unfortunately, some patients
have poor outcomes and die despite optimal medical management by human clinicians, and these
events are taken into account when evaluating the clinician’s policy and are ignored when evaluating
the AI policy; since the AI agent can learn to avoid dosing patients who are very sick, or the AI
agent can learn to “game the system” by just acting differently than the clinician in tough cases.
As a consequence of importance sampling, and due to a lack of understanding of causal links, the
AI Clinician learns the association between the aforementioned interventions and the poor outcome,
and thus avoids recommending these optimal clinical actions in order to not be penalized for the
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Figure 5: Comparison between the AI Clinician’s recommendations at a given point and the clini-
cian’s actual medication doses. The RL agent (AI Clinician) seems to be reluctant to to dose this
patient (see hours 20-35), but why?
death of the patient. This introduces significant bias when estimating the expected value of the AI
Clinicians policy as the AI Clinician does not get graded on the tough cases.
5.2 Limitations of Long-Term Rewards
IV fluids and vasopressors are used to treat hypotensive episodes in septic patients over a short pe-
riod of time, but these interventions do not treat the underlying causes of sepsis. In general, clinical
decision-making strikes balance between short-term (e.g. maintaining a physiologic MAP or ap-
propriate hourly urine output) and long-term outcomes (e.g. preventing kidney injury or mortality).
The approach used by Komorowski et al. focuses only on long-term outcomes: 90-day mortality,
or in-hospital mortality if they do not have the 90-day mortality data. The work entirely ignores
short-term rewards (e.g. maintaining physiologic blood pressure) preventing the AI Clinician from
learning the crucial relationship between IV fluid and vasopressor dosing and MAP. Omitting in-
termediate rewards ultimately allows the AI Clinician to learn non-standard clincical behaviors that
may have deleterious consequences (e.g. giving vasopressors to a normotensive patient). Ironically
these authors raise their disdain for omitting intermediate rewards in RL work in a recent commen-
tary that was also published in Nature Medicine [8].
6 System Representation
6.1 Trajectory Discretization
The authors reduce all of the patient information into four hour summaries or “bins.” This is ade-
quate for static variables (like race and co-morbid conditions), and even some dynamic laboratory
variables like leukocyte count, which does not change dramatically minute-to-minute, or even hour-
to-hour. However, in septic patients some variables like heart rate, blood pressure, and urine output
can undergo rather impressive changes over the course of four hours and patients undergoing rapid
deterioration in their health are the ones in most need of treatment. Down-sampling patient data into
four hour bins severely limits the AI Clinician’s ability to detect and respond to these episodes of
deterioration.
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Vasopressor therapy is a highly reactive intervention. Vasopressors work by constricting the blood
vessels and increasing the contractility of the heart to increase blood pressure. If a clinician has
a septic patient with low MAP (e.g. below 65 mm Hg [7]), they will consider putting them on
vasopressors to increase blood pressure. The dose-to-response time of vasopressors is nearly instan-
taneous. The four-hour bins, utilized by Komorowski et al., fail to adequately capture how quickly
this process happens, and does not capture the relationship between states and actions.
Within a four-hour bin, it is possible for a patients MAP to plummet, a clinician to intervene with
vasopressors, and MAP to recover. The summary for this bin could show that the patient has normal
MAP, yet was administered vasopressors. The AI Clinician could learn from this state and action
that it is optimal to give vasopressors to patients with normal MAPs.
6.2 States, Actions, and Transitions
As mentioned above, the authors map four-hours of patient observations to one of the 750 pre-
defined states. That is, each combination of heart rate, blood pressure, and pre-existing conditions
are reduced to 750 states. Transition matrices created in this way are incapable of capturing the tem-
poral trends required for assessing the treatment needs of a patient, as they only provide information
about the current and next state. The implication of this design is that low frequency events (i.e.
rapid decompensation) are all but ignored by the AI Clinician.
The proposed in silico model is biased towards healthier patients which comprise nearly two thirds
(Figure 8) of the populations in both cohorts. Together with the importance sampling-based evalua-
tion metrics, this explains why the zero drug policy appears to be such a successful dosing policy.
7 Interpretability
The authors state that their proposed model is interpretable, however, a close examination reveals
that the “interpretability” analysis presented by the authors is misleading at best. Supplementary
Figure 2 caption describes the interpretability method used by Komorowski et al:
We built classification random forest models to predict whether the medications
were (clinicians policy) or should have been (AI policy) administered (regard-
less of the dose), using patient variables as input data . . . . Then, the relative
importance of each variable was estimated . . . .This confirmed that the decisions
suggested by the reinforcement learning algorithm were clinically interpretable
and relied primarily on sensible clinical and biological parameters . . .
This analysis is flawed on at least three different levels:
7.1 The Proposed Method has Nothing to do with Interpretability
The proposed method only reveals the top factors contributing to the discrepancy between the clin-
ical policy and the AI clinician policy. It says nothing about the interpretability of the individual
dosing decisions made by the AI clinician. To elucidate why this distinction is important, let us
consider a hypothetical scenario. Consider a new policy (policy-X) that follows the clinical policy
when the patient has a low to moderate comorbidity index [9], and withdraws treatments when the
patient has a high comorbidity index. In this case, the interpretability model proposed by the authors
simply reveals the top factors contributing to the comorbidity index, and on the subset of patients
with low to moderate comorbidity index the method reveals nothing about the clinical rationale for
the treatments proposed by the clinical policy and/or the policy-X.
7.2 Random Forest Gives Random Variations in Importance
The authors provide separate “feature importance” plots for the clinician’s policy and AI policy. In
a binary classification task, these two plots should be essentially identical. The differences that we
observe has little to do with the “feature importance,” and is purely an artifact of utilizing a random
forest model.
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7.3 Individual Actions Are Not Interpretable
Assuming all the analysis was performed correctly (and assuming no other confounding factor fac-
tors affecting the dosing policy), still the method of “feature importance” says nothing about the
AI agent’s reasoning for the individual dosing recommendations. At best, this method is a global
measure of interpretability (over all time points and all patients).
8 Externally Validated?
The importance of externally validating a machine learning model on a data set different than the
training cohort is an absolute minimum if one hopes to claim that the work can be generalized to
other institutions. It shows that the model is robust and does not over fit a single data set.
Komorowski et al. address the issue of external validation by considering a cohort of 3.3 million
ICU patients provided by their industry partner, Philips Healthcare, a medical device manufacturer
with a division dedicated to monetizing healthcare analytics in Baltimore, Maryland.
Close inspection of the data sets used in this work creates almost as many questions as it answers.
We have listed our top concerns below in no particular order; however, we leave the reader to arrive
at their own conclusion on whether the eRI dataset provided by Philips Healthcare really provided a
valid validation dataset for this study.
8.1 Sepsis Incidence
What is the incidence of sepsis in the 3.3 million Philips Healthcare patients? It is impossible to
determine this from the data seen provided by the authors. Using the numbers they provide in Figure
6 one gets the absurd value of 83.5% for the incidence of sepsis, which is clearly due to their biased
exclusion criteria. However, from the data presented, it is not possible to calculate the incidence of
sepsis in the cohort. For the MIMIC-III data set one can determine that it had an incidence of 31.4%
which is also higher than expected, but much more reasonable. Furthermore, the authors admit to
using a “modified definition” of sepsis to determine inclusion in the final cohort. These two issues
make it very challenging to evaluate the validity of the eRI cohort.
Figure 6: Comparison of the MIMIC cohort (left) and the eRI cohort (right). Figure taken from
appendix of [1].
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8.2 Data Quality
In describing the Philips Healthcare data set the authors state that given that our analysis resolution
was 4 h, we expected at least six records [of fluids/vasopressors] per day. Since these records are
counted before binning, this begs the question whether these six records could have been taken all
within a given time bin (or within an hour for that matter), leaving the remaining 5 time bins (20
hours) with no records of vasopressors and fluids. In contrast, the quality of data in the MIMIC
database does seem to be higher with “20.4 intravenous fluids records and 31.1 vasopressor records
[per day].” When one recognizes that 1.66 million patients (49%) from the original data set were
excluded from consideration in round one (Figure 6) for missing data it seriously calls into question
the quality of the remaining data (only 2.3% of the data made it into the final analysis).
8.3 AI Fails in the Philips Healthcare Dataset
When the AI Clinician operates inside the MIMC-III data set there appears to be expected punish-
ments for both under-dosing and over-dosing fluids (Figure 7, Top Left). However when the AI
Clinician begins to treat patients in the Philips Healthcare dataset (Figure 7, Bottom Left) it appears
as though under-dosing patients with IV fluids by as much as 1.2 L, has no effect on the mortality,
while it nearly doubles the mortality rate within the MIMIC database. The substantial difference
between the dose response to vasopressors between the two cohorts is also concerning, and leads
one to question whether or not the AI Clinician actually has similar performance between the two
datasets.
It is worth noting that using these curves alone (Figure 7), one cannot evaluate the AI Clinician’s
performance, as an individual dose-mortality pair does not take into account confounding factors,
such as baseline comorbidities and whether or not a patient received antibiotics in a timely manner.
For example, a patient who gets 800 mL of extra fluid (over a 4 hour window) compared to the AI
Clinician may have been sicker at the baseline, and the AI Clinician may have decided to withdraw
treatment (see the section Evaluation Bias).
9 The Wrong Cohort Entirely
The authors train and evaluate the AI Clinician on patients that meet Sepsis-3 criteria from two
different data sets, but is this the right group to evaluate? At point85 we’d say no for the two reasons
listed below.
9.1 Unnecessary AI
As we discuss previously, the method of evaluating the AI Clinicians performance disproportionately
rewards actions that are different from the clinician (often inaction when the clinician is significantly
intervening). As seen in Figure 8 only one-third of either cohort ever received a vasoactive drug, and
from this information one could safely assume that only one-third of the patient cohort experienced
clinically significant hypotension. The take home point is that of all the patients that Komorowski
et al. examined, nearly two-thirds received no vasopressor treatments in their ICU course, meaning
that two-thirds of the patients had no need for the AI Clinician’s intervention. It is not surprising
that the “zero drug” policy then had such a high expected reward.
9.2 Iatrogenic Treatment
To date, all evidence-based practices regarding the treatment of sepsis reserve the use of vasopres-
sors to those patients suffering from hypotension, invariably defined as a MAP < 65. It would be
considered universally iatrogenic to administer a normotensive patient vassopressors. Unfortunately,
there is no guarantee that the AI Clinician won’t make this mistake. The lack of intermediate re-
wards and the use of four-hour binning previously described means that there is ample opportunity
for the AI Clinician to have learned to give normotensive patients vasopressors.
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Figure 7: Comparison of the MIMIC (top) and eRI (bottom).
Figure 8: One can safely assume that only about one-third of either cohort warranted any consider-
ation by the AI Clinician, meaning that for two-thirds of the either cohort the AI Clinician prowess
was rewarded as it recommended doing nothing.
10 Final Comments
We have gone to great lengths to fairly examine and reproduce this work. The corresponding authors
have yet to provide access to their source code, which we requested in October 2018. Studies such
as the work by Komorowski et al. and academic journals seeking to retain a dwindling readership
through the hasty promotion of impressive but unvetted claims are contributing to an erosion of
public trust and are precipitating the “big-data winter” cautioned by Michael Jordan.
“Before the Second World War meteorology had been a bit like medicine in the nineteenth century:
the demand for expertise was so relentless that the supply had no choice but to make fraudulent
appearances.” -The Coming Storm[10]
On 2/4/19 Dr. Faisal Aldo provided a link to the GitHub repository containing MatLab code nec-
essary for reproducing parts of their work. We will attempt to apply this code to the cohort that we
selected for this post; however, reproduction of the exact cohort used by Komorowski et al. without
more specific guidance may not be possible. The most time consuming step in this field is pre-
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processing a dataset for evaluation by the algorithm (e.g. how were missing values handled, which
of the many, many infusions in MIMIC-III were selected & which were discarded?).
The code generated by Jeter et al. that accompanies this paper can be found here:
https://github.com/point85AI/Policy-Iteration-AI-Clinician
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